Open AccessPD-1 Blockers
Author(s) -
Jedd D. Wolchok
Publication year - 2015
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2015.07.045
Subject(s) - nivolumab , pembrolizumab , biology , monoclonal antibody , metastatic melanoma , antibody , melanoma , monoclonal , immune system , receptor , cancer research , lung cancer , pharmacology , immunotherapy , immunology , oncology , medicine , genetics
Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer. To view this installment of Bench to Bedside, open or download the PDF
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom